XML 31 R22.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Nature of Operations and Summary of Significant Accounting Policies (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Accounting Policies [Abstract] |
Schedule of Correction of Immaterial Error | The table below sets forth the impact of the revision on the previously issued consolidated balance sheet:
| December 31, 2020
| As Previously |  | (i) |  | (ii) |  | (iii) |  |
| Reported |  | Adjustments |  | Adjustments |  | Adjustments |  | As Adjusted
ASSETS |  |  |  |  |  |  |  |  |
Accounts receivable, net | 1,850,499 |  |  | — |  |  | 212,722 |  |  | — |  |  | 2,063,221 |
Total current assets | 25,133,704 |  |  | — |  |  | 212,722 |  |  | — |  |  | 25,346,426 |
Deferred tax assets | 8,007,633 |  |  | 22,154 |  |  | (44,672) |  |  | (43,679) |  |  | 7,941,436 |
Total assets | $ | 65,732,843 |  |  | $ | 22,154 |  |  | $ | 168,050 |  |  | $ | (43,679) |  |  | $ | 65,879,368 |
LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |  |
Deferred revenue from company clinics | 3,905,200 |  |  | 296,348 |  |  |  |  | (524,993) |  |  | 3,676,555 |
Total current liabilities | 18,685,644 |  |  | 296,348 |  |  | — |  |  | (524,993) |  |  | 18,456,999 |
Total liabilities | 44,981,760 |  |  | 296,348 |  |  | — |  |  | (524,993) |  |  | 44,753,115 |
Stockholders' equity: |  |  |  |  |  |  |  |  |
Accumulated deficit | (20,470,081) |  |  | (274,194) |  |  | 168,050 |  |  | 481,314 |  |  | (20,094,912) |
Total The Joint Corp. stockholders' equity | 20,750,983 |  |  | (274,194) |  |  | 168,050 |  |  | 481,314 |  |  | 21,126,152 |
Total equity | 20,751,083 |  |  | (274,194) |  |  | 168,050 |  |  | 481,314 |  |  | 21,126,252 |
Total liabilities and stockholders' equity | $ | 65,732,843 |  |  | $ | 22,154 |  |  | $ | 168,050 |  |  | $ | (43,679) |  |  | $ | 65,879,368 |
Schedule of Franchisor Disclosure | The following table summarizes the number of clinics in operation under franchise agreements and as company-owned or managed clinics for the three and nine months ended September 30, 2022 and 2021:
| Three Months Ended September 30, |  | Nine Months Ended September 30, |  |
Franchised clinics: | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |
Clinics open at beginning of period | 662 |  |  | 555 |  |  | 610 |  |  | 515 |  |  |  |  |
Opened during the period | 33 |  |  | 28 |  |  | 91 |  |  | 76 |  |  |  |  |
Acquired during the period | 1 |  |  | — |  |  | 1 |  |  | — |  |  |  |  |
Sold during the period | (4) |  |  | — |  |  | (8) |  |  | (8) |  |  |  |  |
Closed during the period | (2) |  |  | — |  |  | (4) |  |  | — |  |  |  |  |
Clinics in operation at the end of the period | 690 |  |  | 583 |  |  | 690 |  |  | 583 |  |  |  |  |
| Three Months Ended September 30, |  | Nine Months Ended September 30, |  |
Company-owned or managed clinics: | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |
Clinics open at beginning of period | 107 |  |  | 78 |  |  | 96 |  |  | 64 |  |  |  |  |
Opened during the period | 5 |  |  | 5 |  |  | 12 |  |  | 11 |  |  |  |  |
Acquired during the period | 4 |  |  | — |  |  | 8 |  |  | 8 |  |  |  |  |
Sold during the period | (1) |  |  | — |  |  | (1) |  |  | — |  |  |  |  |
Closed during the period | — |  |  | — |  |  | — |  |  | — |  |  |  |  |
Clinics in operation at the end of the period | 115 |  |  | 83 |  |  | 115 |  |  | 83 |  |  |  |  |
Total clinics in operation at the end of the period | 805 |  |  | 666 |  |  | 805 |  |  | 666 |  |  |  |  |
Clinic licenses sold but not yet developed | 212 |  |  | 252 |  |  | 212 |  |  | 252 |  |  |  |  |
Licenses for future clinics subject to executed letters of intent | 40 |  |  | 43 |  |  | 40 |  |  | 43 |  |  |  |  |
Schedule of Earnings (Loss) per Common Share |
| Three Months Ended September 30, |  | Nine Months Ended September 30, |  |
| 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |
Net income | $ | 491,113 |  |  | $ | 1,937,095 |  |  | $ | 630,058 |  |  | $ | 6,935,751 |  |  |  |  |
Weighted average common shares outstanding - basic | 14,512,856 |  |  | 14,388,905 |  |  | 14,474,323 |  |  | 14,286,818 |  |  |  |  |
Effect of dilutive securities: |  |  |  |  |  |  |  |  |  |  |
Unvested restricted stock and stock options | 316,773 |  |  | 581,423 |  |  | 403,727 |  |  | 644,941 |  |  |  |  |
Weighted average common shares outstanding - diluted | 14,829,629 |  |  | 14,970,328 |  |  | 14,878,050 |  |  | 14,931,759 |  |  |  |  |
Basic earnings per share | $ | 0.03 |  |  | $ | 0.13 |  |  | $ | 0.04 |  |  | $ | 0.49 |  |  |  |  |
Diluted earnings per share | $ | 0.03 |  |  | $ | 0.13 |  |  | $ | 0.04 |  |  | $ | 0.46 |  |  |  |  |
The following common stock equivalents were excluded from the computation of diluted earnings per share for the periods presented because including them would have been antidilutive:
| Three Months Ended September 30, |  | Nine Months Ended September 30, |  |
Weighted average dilutive securities: | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |
Restricted stocks | — |  |  | — |  |  | — |  |  | — |  |  |  |  |
Stock options | 77,485 |  |  | 601 |  |  | 41,293 |  |  | 35,293 |  |  |  |  |

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794 + Details
Name: | us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of franchisors that are included in the discussion of the nature of an entity's operations. + References No definition available. + Details
Name: | us-gaap_ScheduleOfFranchisorDisclosureTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration